

## Special Issue

# Vaccines for COVID-19

### Message from the Guest Editors

Three years after the spread of SARS-CoV-2, the virus responsible for the last global pandemic event, we can take stock of the past, present, and future of the SARS-CoV-2 virus. This includes, on one hand, the about 7 million deaths around the world caused by the virus (though this number could be an underestimation), but also, on the other, the vast range of pharmacological measures and vaccine options that did not exist in 2020. Because of the pandemic, health systems globally bordered on collapse, having to deal with extreme numbers of simultaneous cases. The situation today is far more manageable, though the virus continues to circulate and remains challenging to eradicate. The topics that I invite you to reflect on are as follows:

- The impact of vaccination on the general population;
- The impact of vaccination on the elderly population;
- The impact of vaccination on the population of so-called fragile subjects (immunosuppressed, sick, those with oncological problems or heart disease, etc.).

---

### Guest Editors

Dr. Filippo Luciani

Infectious Diseases Unit of Annunziata Hospital, 87100 Cosenza, Italy

Dr. Erika Cione

1. Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy

2. Galascreen Laboratories, University of Calabria, 87036 Rende, Italy

---

### Deadline for manuscript submissions

closed (7 October 2023)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/162058](https://mdpi.com/si/162058)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

---

### Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College  
Roosevelt, 4331 CB Middelburg, The Netherlands

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).